Lactobacillus rhamnosus is a beneficial bacterium that lives naturally in the human gut and is one of the most widely studied probiotics in the world. It belongs to the Lactobacillus genus, a large family of bacteria found throughout the digestive and urogenital tracts. Its most famous strain, L. rhamnosus GG (often called LGG), was isolated from a healthy human adult by researchers Sherwood Gorbach and Barry Goldin in the 1980s, with the “GG” coming from their surnames.
Basic Biology
L. rhamnosus is a rod-shaped, Gram-positive bacterium that doesn’t form spores. It’s classified as anaerobic, meaning it thrives without oxygen, but it’s also aerotolerant, so it can survive in environments where oxygen is present. It produces lactic acid through fermentation, which is one reason it’s so common in fermented dairy products. The strain LGG was originally isolated from the gut of a healthy infant, though it colonizes human intestines across all age groups.
How It Sticks to Your Gut
What sets L. rhamnosus apart from many other probiotics is its ability to physically attach to the intestinal lining and stay there. It does this using tiny hair-like structures called pili on its surface. These pili, encoded by a gene cluster called spaCBA, act like grappling hooks that reach through the bacterium’s outer coating and latch onto the mucus layer of your intestinal wall. Research on the LGG strain has confirmed that these pili are the key factor in its strong adhesion to intestinal cells and its ability to form biofilms, essentially protective colonies that help it persist in the gut rather than simply passing through.
This adhesion matters because a probiotic that can’t stick around long enough to interact with your immune system or compete with harmful bacteria provides limited benefit. The pili give LGG a meaningful advantage over probiotic strains that lack them.
Digestive Benefits
The best-supported use of L. rhamnosus is preventing diarrhea caused by antibiotics. Antibiotics kill harmful bacteria but also wipe out beneficial ones, leaving the gut vulnerable. A meta-analysis of 11 randomized controlled trials involving over 1,300 people found that LGG cut the risk of antibiotic-associated diarrhea roughly in half, from 22.4% to 12.3% compared to placebo.
The effect was especially strong in children. Across five pediatric trials with 445 participants, diarrhea rates dropped from 23% to 9.6% in children taking LGG. In adults, the benefit was most clearly significant in those taking antibiotics to treat H. pylori infections, a common cause of stomach ulcers, where LGG reduced diarrhea risk by about 74%.
Immune System Effects
L. rhamnosus doesn’t just sit in your gut passively. It actively communicates with your immune system. Research published in the Journal of Clinical Investigation found that LGG triggers a specific type of immune cell in the intestinal lining to produce IL-10, an anti-inflammatory signaling molecule. This creates a feedback loop: the IL-10 calms those same immune cells down, which in turn suppresses the production of inflammatory molecules like TNF-alpha, IL-6, and IL-1b.
In animal studies of inflammatory colitis, oral LGG more than doubled IL-10 production in these intestinal immune cells while simultaneously lowering inflammatory markers. The practical significance is that L. rhamnosus appears to help the immune system dial down overreaction without suppressing it entirely. It nudges the system toward balance rather than simply boosting or dampening it.
Eczema Prevention in Children
One of the more compelling applications of L. rhamnosus is in reducing childhood eczema, particularly when mothers take it during pregnancy and continue supplementation in infants. A systematic review and meta-analysis of 11 randomized trials found that perinatal use of L. rhamnosus reduced the incidence of atopic eczema by about 40% in children up to age 2 (relative risk 0.60). That protective effect held through ages 6 to 7, with a 38% reduction in eczema risk.
The benefit appeared to fade at later follow-ups. By ages 4 to 5 and 10 to 11, the reductions were no longer statistically significant. High dropout rates across the studies also temper these findings somewhat. Still, the early-life protection is notable enough that several professional guidelines have acknowledged L. rhamnosus as a reasonable consideration for families with a history of allergic conditions.
Vaginal Health
A different strain, L. rhamnosus GR-1, has been studied specifically for its effects on vaginal health. In a randomized trial of 64 healthy women, taking L. rhamnosus GR-1 orally (combined with another Lactobacillus strain) for 60 days significantly shifted vaginal flora toward a healthier profile. Among women who started with asymptomatic bacterial vaginosis, 37% saw their vaginal microflora return to normal compared to just 13% on placebo.
Perhaps more striking was the preventive effect. None of the women in the probiotic group developed bacterial vaginosis during the study, while 24% of women on placebo did. The treatment also significantly reduced vaginal yeast and harmful coliform bacteria, with the protective effect persisting up to a month after supplementation stopped. This was the first probiotic combination shown to reduce vaginal colonization by pathogenic bacteria and yeast when taken by mouth rather than applied locally.
Where to Find It
L. rhamnosus is available in supplement form, most commonly as capsules or powders. The brand Culturelle, for example, contains the LGG strain. Clinical trials have typically used doses in the range of 2.5 to 5 billion colony-forming units (CFU) per day, though dosing varies by condition and study.
You can also get L. rhamnosus through fermented foods. It has a long history in dairy fermentation and is commonly found in yogurt, where it’s sometimes added alongside traditional starter cultures. Beyond dairy, it has been successfully used to ferment millet, maize, and fruit juices. In East Africa, community-produced probiotic yogurts containing L. rhamnosus GR-1 or LGG have reached over 250,000 consumers, with school-based studies showing reductions in skin allergies and diarrhea among children who consumed the yogurt daily.
Safety Considerations
For the vast majority of people, L. rhamnosus has an excellent safety record across decades of use and hundreds of clinical trials. It’s generally well tolerated with minimal side effects, which occasionally include mild gas or bloating when first starting supplementation.
The important exception involves people with severely compromised immune systems, organ failure, or disrupted gut barriers. Case reports have documented rare instances of L. rhamnosus causing bloodstream infections in critically ill patients, including those recovering from cardiac surgery. This isn’t unique to L. rhamnosus; it’s a risk with live probiotic bacteria in general when the body’s normal defenses are significantly weakened. If you have a serious underlying health condition or are immunocompromised, probiotics should be discussed with a healthcare provider before use.